Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Divi's Laboratories Ltd.
NSE: DIVISLAB
|
BSE: 532488
|
ISIN: INE361B01024
|
Industry: Pharmaceuticals
|
Expensive Performer
6052.5000
-40.00
(
-0.66
%)
NSE
Sep 23, 2025
15:20 PM
Volume:
243.2K
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Divi's Laboratories Ltd.
07 Nov 2020
6052.50
-0.66%
Divi's Labs (ADD): Flawless execution drives Q2 beat upgrade to ADD
Accumulate:
Divi's Laboratories Ltd.
by
BOB Capital Markets Ltd.
Target: 3520
Recommendation
Target
BOB Capital Markets Ltd.
Divi's Labs (DIVI) retained its strong execution in Q2, reporting an 18% EBITDA beat.
Divi's Laboratories Ltd. is trading below all available SMAs
More from Divi's Laboratories Ltd.
Recommended
Market trades flat, HCC bags two orders worth Rs 2,566 cr
Trendlyne Marketwatch |
23 Sep 2025, 03:09PM
IPO market heats up: 29 new offerings and 8 listings this week
|
22 Sep 2025, 05:34PM
Custom synthesis business drives growth for Divi’s Laboratories
|
10 Mar 2022